Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04979650 (ClinicalTrials.gov)	May 22, 2021	2/7/2021	Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis	Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023	Multiple Sclerosis, Relapsing-Remitting;Magnetic Resonance Imaging;Methylprednisolone	Drug: Methylprednisolone succinate;Drug: Normal saline	Mazandaran University of Medical Sciences	NULL	Enrolling by invitation	18 Years	55 Years	All	104	Phase 2	Iran, Islamic Republic of
2	NCT04660539 (ClinicalTrials.gov)	March 2, 2021	24/11/2020	A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)	A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Drug: satralizumab;Drug: azathioprine (AZA);Drug: mycophenolate mofetil (MMF);Drug: oral corticosteroids	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	N/A	All	119	Phase 3	United States;Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Puerto Rico;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom
3	NCT03752307 (ClinicalTrials.gov)	February 15, 2019	15/11/2018	Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses	Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse	Multiple Sclerosis	Drug: Isoxsuprine Hydrochloride;Drug: Placebo;Drug: Corticosteroid	University of New Mexico	NULL	Completed	18 Years	50 Years	All	2	Phase 1/Phase 2	United States
4	NCT03605238 (ClinicalTrials.gov)	August 15, 2018	29/6/2018	Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20	Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Biological: Corticosteroids & tanCART19/20	Chinese PLA General Hospital	NULL	Withdrawn	12 Years	75 Years	All	0	Phase 1	China
5	NCT04450030 (ClinicalTrials.gov)	August 1, 2018	24/6/2020	Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis	Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis - Assessment of Mechanism of Action	Multiple Sclerosis, Relapsing-Remitting	Drug: Methyl Prednisolonate;Procedure: Immunoadsorption	University Hospital Muenster	NULL	Active, not recruiting	18 Years	65 Years	All	204		Germany
6	NCT02784210 (ClinicalTrials.gov)	October 5, 2016	26/5/2016	Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study	Multiple Sclerosis	Drug: Methylprednisolone;Drug: Prednisone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
7	NCT02296346 (ClinicalTrials.gov)	October 2014	18/11/2014	Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis	A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)	Secondary Progressive Multiple Sclerosis	Drug: SoluMedrol;Device: Extracorporeal Photopheresis	University of Utah	Mallinckrodt	Terminated	18 Years	75 Years	All	13	N/A	United States
8	NCT00418145 (ClinicalTrials.gov)	September 2003	2/1/2007	Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks	Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)	Multiple Sclerosis	Drug: megadose oral methylprednisolone;Drug: IV methylprednisolone	Fred Lublin	National Multiple Sclerosis Society;Pfizer	Terminated	18 Years	50 Years	All	16	Phase 3	United States

先頭へ